Domača stranLCTX • NYSEAMERICAN
add
Lineage Cell Therapeutics Inc
Prejšnji trg. dan.
0,92 $
Dnevni razpon
0,84 $ - 0,93 $
Letni razpon
0,84 $ - 1,61 $
Tržna kapitalizacija
168,34 mio. USD
Povprečni obseg
1,07 mio.
Razm. P/E
-
Dividendna donosnost
-
Borzne novice
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
| (USD) | mar. 2024info | Sprememba L/L |
|---|---|---|
Prihodek | 1,44 mio. | −39,48 % |
Stroški poslovanja | 5,00 mio. | 5,78 % |
Čisti dohodek | −6,54 mio. | −49,63 % |
Čista dobičkovnost prihodkov | −453,05 | −147,24 % |
Earnings per share | −0,04 | −54,62 % |
EBITDA | −6,49 mio. | −0,23 % |
Efektivna davčna stopnja | — | — |
Bilanca stanja
Skupna sredstva
Skupne obveznosti
| (USD) | mar. 2024info | Sprememba L/L |
|---|---|---|
Denar. in kratkor. naložbe | 43,62 mio. | −6,82 % |
Skupna sredstva | 108,48 mio. | −4,17 % |
Skupne obveznosti | 37,49 mio. | −15,16 % |
Celoten lastniški kapital | 70,99 mio. | — |
Shares outstanding | 188,80 mio. | — |
Razmerje P/B | 2,42 | — |
Donosnost sredstev | −15,90 % | — |
Donosnost kapitala | −23,92 % | — |
Denarni tok
Neto sprememba denarnih sredstev
| (USD) | mar. 2024info | Sprememba L/L |
|---|---|---|
Čisti dohodek | −6,54 mio. | −49,63 % |
Denar iz dejavnosti | −5,78 mio. | 48,56 % |
Denar iz naložb | −38,00 tis. | −100,25 % |
Denar iz financiranja | 14,02 mio. | 1.402.000,00 % |
Neto sprememba denarnih sredstev | 8,13 mio. | 99,02 % |
Prost denarni tok | −3,30 mio. | 41,32 % |
Vizitka
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Wikipedia
Datum ustanovitve
1990
Spletno mesto
Zaposleni
72
